FDA Inaction May Not Doom GSK Zofran MDL, 1st Circ. Hints
By Chris Villani ( July 26, 2022, 2:06 PM EDT) -- A First Circuit judge suggested Tuesday that a federal agency may not have blessed the label for GlaxoSmithKline's anti-nausea drug Zofran merely by declining to add a warning that it may cause birth defects....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.